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The ability of cells to migrate to specific sites is critical for the proper functioning of both innate and
adaptive immune responses in primates. This selective responsiveness is largely orchestrated by small
proteins known as chemokines, which direct immune cells expressing an array of chemokine receptors
towards concentrations of intracellular and extracellular pathogens. Given the central role of chemokines
and chemokine receptors in mediating immunity as well as homeostasis, it is perhaps not surprising that
many pathogens, including HIV type 1 (HIV-1) and simian immunodeficiency virus (SIV), have targeted
various aspects of chemokine biology. HIV-1 appears only able to use the chemokine receptors CCR5 and
CXCR4 as coreceptors to CD4 to efficiently bind and infect cells in vivo. Interactions between HIV-1 and
humans are thought to have evolved more recently than interactions between SIV and other primate
species. Despite the ability of HIV-1 and SIV to readily mutate under immune pressure and the fact that
CCR5 has undergone a range of adaptations in some primates that reduce the pathogenicity of HIV-1
infection, these viruses have maintained their dependency on the CCR5 coreceptor. This review discusses
these issues of co-adaptation and the potential role and impact of coreceptor antagonists that are
currently being developed for clinical use. J Viral Entry 2005;1(1):17–27.
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One of the fundamental properties that characterizes living
organisms is cellular motility – the ability to polarize and
subsequently move towards or away from a stimulus.
Cellular motility is of central importance for many biological
processes in vertebrates, including embryological
development, the migration of spermatozoa, and the
movement of cell precursors from the bone marrow to
tissues via the circulatory system. The ability of cells to
migrate to specific sites is particularly relevant to the proper
functioning of both innate and adaptive immune responses
in primates. Selective responsiveness is largely orchestrated
by the release and detection of extracellular proteinaceous
ligands. Small proteins known as chemokines are involved in
directing immune effector cells, which express an array of
chemokine receptors, towards intracellular and extracellular
pathogens. Due to the central role that chemokines play in
mediating both immunity and homeostasis, it is not
surprising that many pathogens have targeted various
aspects of chemokine biology, and, as with other targeted
biological systems, there is evidence of a dynamic process of
adaptation that affects both host and pathogen as these
selective pressures shift over time. For a successful pathogen
such as HIV type 1 (HIV-1), adaptation over generations
may be measured in days and weeks, while for the human
host it is possible that the shifting patterns of endemic and 
epidemic pathogens (of which HIV-1 is but one of the most
recent) have guided the evolution of the chemokine system
over centuries. This article reviews the interaction between
chemokine receptors and their endogenous and 
pathogen-derived ligands with a specific focus on the 
role of chemokine–chemokine receptor systems in 
HIV-1 pathogenesis. 
Chemokines and chemokine receptors: Divergent protein
families with different and complementary functions 
To understand the consequences for both the pathogen and
the host that may result from targeting a particular
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chemokine or chemokine receptor for medical intervention, it
is important to review the characteristics of this family of
molecules. Chemokine receptors are members of the
rhodopsin superfamily of receptors and have a characteristic
structure that includes seven transmembrane-spanning 
α-helices. The conventional nomenclature for chemokine
receptors reflects the conserved structural characteristics of
their ligands; thus, CCR5 binds a selection of CC
chemokines. Chemokines are bound via interactions with the
amino terminus and one or more of the extracellular loops of
the receptor. Signal transduction is dependent on the
activation of G-proteins associated with the receptor, which
phosphorylate intracellular targets that stimulate chemotaxis
of the cell towards the source of the chemokine [1].
Chemokines can be broadly divided into two classes 
(Table 1):
• Those secreted in response to a 
proinflammatory stimulus.
• Constitutively expressed chemokines involved 
in homeostasis. 
This functional classification system is distinct from the
structural assignment of chemokines to one of four classes,
which is related to the conserved cysteine residues present
within their receptor-binding sites. In fact, all chemokines
exhibit a highly similar tertiary structure, consisting of a
flexible region located amino-terminally to the CC or CXC
motif, followed by a first loop region (N-loop), three anti-
parallel β-strands, and a carboxy-terminal α-helix (Fig. 1). 
Phylogenetic analysis of the chemokine receptors reveals
a highly divergent family of proteins, with the clustering of
sets of receptor proteins reflecting physical genetic proximity
and, in most cases, overlapping ligand interactions 
(e.g. CCR5, 2, 3, and 1; CXCR1 and 2) (Fig. 2). However,
although the chemokine receptors exhibit low levels of
amino acid similarity, they do retain a high degree of
structural homology, which reflects their interaction with a
restricted number of chemokine ligands.
Properties of chemokine receptors that affect ligand
binding include sulphated tyrosine residues at the amino
terminus that interact with the ligands and which convey an
overall negative charge to this region on the receptor. This
Figure 1. Chemokines have a conserved tertiary structure despite substantial sequence diversity. All chemokines exhibit 
a highly similar tertiary fold, which consists of a flexible region located amino-terminally to the CC or CXC motif followed
by a first loop region (N-loop), three anti-parallel β-strands and a carboxy-terminal α-helix. The 3D structures were created
by Cn3D [75], using published data from the Molecular Modeling Database of the National Center for Biotechnology
Information (National Library of Medicine, National Institutes of Health, Bethesda, MD, USA) [76,77].
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interaction has been demonstrated experimentally for two
of the most promiscuous ligand-binding receptors: CCR5,
which binds a range of CC chemokine ligands (including
HIV-1) [2], and the human Duffy antigen, which uniquely
has both CC and CXC ligand-binding affinities [3]. The same
post-translational tyrosine sulphation is also present on the
other central HIV coreceptor, CXCR4 [4]. However,
additional structural characteristics of the amino terminus
seem to be more important than the interactions with
sulphated tyrosine residues in determining the specificity of
these receptors. The specificity of CCR2 for its ligands
(CCL2, 7, 12, and 13), and of CCR3 for its ligands (CCL3, 5,
7, 8, 11, 13, 15, 24, and 26) appears to depend on intrinsic
characteristics of the amino termini of the receptors, but also
Table 1A. Inflammatory/inducible chemokine receptors and ligands.
Receptor Ligand(s) Receptor Ligand(s)
CCR1 CCL3L1/MIP-α
CCL5/RANTES
CCL7/MCP-3
CCL9/MIP1-γ
CCL14/HCC-1
CCL15/HCC-2
CCL16/HCC-4
CCR2 CCL2/MCP-1
CCL7/MCP-3
CCL12/mouse MCP-5
CCL13/MCP-4
CCR3 CCL3L1/MIP-1α
CCL5/RANTES
CCL7/MCP-3
CCL8/MCP-2
CCL11/eotaxin
CCL13/MCP-4
CCL15/HCC-2
CCL24/eotaxin-2
CCL26/eotaxin-3
CCR4 CCL17/TARC
CCL22/MDC
CCR5 CCL3/MIP-1α
CCL4/MIP-1β
CCL5/RANTES
CCL8/MCP-2
CCR8 CCL1/I309
CCL4/MIP-1β
CCR10 CCL27/CTACK
CCL28
CCR11 CCL2/MCP-1
CCL8/MCP-2
CCL13/MCP-4
XCR1 XCL1/lymphotactin  α
XCL1/lymphotactin β
CXCR1 CXCL2/Gro-β
CXCL3/Gro-γ
CXCL5/ENA-78
CXCL6/GCP-2
CXCL7/NAP-2
CXCL8/IL-8
CXCR2 CXCL1/Gro-α
CXCL2/Gro-β
CXCL3/Gro-γ
CXCL5/ENA-78
CXCL6/GCP-2
CXCL7/NAP-2
CXCL8/IL-8
CXCR3 CXCL9/Mig
CXCL10/IP-10
CXCL11/I-TAC
CXCR3B CXCL4/PL4
CX3CR1 CX3L1/Fractalkine
CCL6/C10 Unidentified
CCL10 Unidentified
CCL18/DC-CK1 Unidentified
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Table 1B. Constitutive/homeostatic chemokine receptors and ligands.
Receptor Ligand(s) Receptor Ligand(s)
CCR6 CCL20/MIP3-α
CCR7 CCL19/MIP3-β CCL21/6kine
CCR9 CCL25/TECK
CCR10 CCL27/CTACK
CXCR4 CXCL12/SDF-1
CXCR5 CXCL13/BLC
CXCR6 CXCL16
CXCR7 CXC12/SDF-1
CX3CR1 CX3CL1/Fractalkine
Unidentified CCL18/DC-CK1
Unidentified CCL23/MPIF-1
Unidentified CXCL14/BRAC
Unidentified CXCL15/LungkineTHE JOURNAL OF VIRAL ENTRY Vol 1 No 1 2005 20
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requires interactions with extracellular loop domains for
maximal signaling [5]. Interestingly, this is not true for CCR5
and its ligands (CCL3, 4, 5, and 8), where experimental
swapping of its amino terminus with that of CCR2 does not
change its ligand-binding selectivity [6].
The cellular components of the early pro-inflammatory
response are governed in part through the selective
expression of chemokine receptors by monocytes (chiefly
CCR2–5), neutrophils (CXCR1 and 2) and eosinophils
(CCR3) and by the temporal or tissue-specific secretion of
chemokines [7,8]. This means that a given pathogenic
stimulus in a specific tissue will generate a distinct local
chemokine profile that influences the resulting cell infiltrate
(eosinophils in the lung, neutrophils in the gut, and
monocytes and neutrophils in the skin) [7,9–11]. Nearly all
inflammatory chemokine receptors bind multiple high-
affinity ligands (Table 1). Constitutive chemokine secretion
exists in many tissues, and responsiveness to these gradients
is regulated by the expression of suitable chemokine
receptors by responsive cells. This is important for the
homeostasis of many cell populations in peripheral tissues,
such as the trafficking of dendritic cell (DC) precursors and
activated T cells to the skin [12,13], the access and egress of
naïve T cells to and from lymph nodes [14], the migration of
maturing DC to lymph nodes [15], and the positioning of 
B cells within lymph nodes [16]. 
Taken together, the chemokine–chemokine receptor
system shows both redundancy (ensuring the maintenance
of vital processes in case of the loss of certain 
molecules), and specificity (allowing a targeted response to 
specific stimuli).
Viral subversion of the chemokine–chemokine 
receptor system 
As mentioned above, the range of chemokines that interact
with one or more chemokine receptors during an
inflammatory response is broad; thus, the blockade of a
single chemokine–chemokine receptor interaction might
have little effect in limiting the inflammatory response.
Indeed, this has been revealed in the generation of
genetically modified mice with a single proinflammatory
chemokine (CCL11, CCL3, or CCL5) “knocked out”
[17,18]. In contrast, the targeted deletion of a chemokine
receptor gene often has more profound effects on cell
recruitment (CCR2, CCR5, or CCR7) [18–20], although only
the deletion of CXCR4 has proved embryonically lethal in
knockout mice [21]. The overlapping and frequently
redundant nature of this signaling system is also reflected in
the capacity of many viral proteins to bind host chemokines
or chemokine receptors, such as the 35 kDa protein of the
vaccinia virus and the MC148R protein of the Molluscum
contagiosum virus [22,23]. The broad chemokine binding
properties of these viral proteins are provoking much
interest as potential anti-inflammatory agents at present
[24]. While broadly directed chemokine–chemokine receptor
binding represents a generic strategy to limit the host
immune response, some viruses also employ alternative
approaches to manipulate components of the immune
response, including the production of chemokine agonists,
such as vMIP2 by Kaposi’s sarcoma-associated herpes virus
and the US28 protein by human cytomegalovirus [25,26],
as well as viral chemokine receptor analogues [27]. Both of
these approaches are thought to promote the recruitment of
target cells to a site of active viral replication in order to aid
the local spread of infection. For a more detailed discussion
on the breadth of viral immune escape see recent reviews by
Murphy and Lucas and colleagues [28,29].
A number of lentiviruses, including HIV-1 and the simian
immunodeficiency virus (SIV), use a different strategy in
their targeting of the chemokine–chemokine receptor
system of their primate hosts. They produce molecular
mimics of endogenous chemokines that are used to gain
entry into the target cells through binding of a 
range of host cell surface receptors, including chemokine
receptors. The following section aims to review 
evolutionary and current aspects of these adaptable 
host–pathogen interactions.
Entry via the front door: An ancient strategy 
The targeting of CCR5 and CXCR4 by HIV-1 in humans is
thought to be a recent pathogenic threat; thus, human
population genetics may show little evidence of an adaptive
response at present. By contrast, closely related viruses such
as SIV appear to have affected primates for long enough to
bring about significant changes in the genetic diversity of
the targeted gene products [30]. The study of different
primate populations has begun to provide insights into the
possible array of host/lentiviral adaptations that have not
yet occurred within the human and HIV-1 genomes. In this
context, it is notable that chimpanzees appear to have lost
significant genetic diversity within the CCR5 receptor locus
[30]. This selective sweep of genetic diversity, which has
also affected the major histocompatibility complex (MHC)
region, suggests an evolutionary “bottleneck” generated
during the chimpanzee encounter with SIV, in which variant
CCR5 (and MHC) alleles conferred a critical survival
advantage. Similarly, the CCR5 locus in the African green
monkey (AGM) appears to show evidence of co-evolution
with SIV isolates from the monkey’s natural habitats. SIV
infection in AGMs is endemic but has a benign clinical
course. Many of the allelic variants present within the AGM
block SIV infection of susceptible cell lines in vitro, withoutCELLULAR TROPISM OF HIV-1 MEDIATED AND CONSTRAINED BY CORECEPTOR DEPENDENCIES
interfering with chemokine–chemokine receptor binding
[31]. Thus, despite encounters with a range of primate
species that might have provided pressure to select for
additional primary coreceptors, the use of CCR5 seems
intrinsic to SIV/HIV-1 viral fitness, and is most probably
linked to successful infection of the target. From the
perspective of the host, it is important to note that CCR5
has not been lost from these primate populations. Instead,
they remain susceptible to a SIV/HIV-1 infection that is
effectively controlled by antiviral immunity, whose efficacy
has been honed by the evolutionary history of the
virus–host interactions described above. This illustrates the
important point that blocking of infection is not the only
route to reducing the pathogenicity of a virus. 
Figure 2. Phylogenetic analysis of the chemokine receptor family reveals a divergent family of proteins with clustering of
receptors with overlapping ligands and close physical genetic proximity. Amino acid sequences of the human, mouse,
bovine, and Xenopus chemokine receptors were aligned using ClustalW followed by manual editing [78]. The resultant
alignment was used in the program MEGA v2.1 to create a Neighbor-Joining tree using the gamma model with pairwise
deletion [79,80]. Receptors with overlapping ligands are indicated by closed circles and diamonds. Receptors in close
genetic proximity on 2q34–q35 and 3p21 are indicated. CCR9, 4, and 8 are located on 3p22–23. Human chemokine
receptors are indicated by name only. 
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In the case of humans, genetic diversity within the
chemokine networks may serve to highlight those biological
processes that are most critical (and least redundant) to
allowing HIV-1 infection to proceed.  
HIV-1 cellular tropism conveyed through 
structural mutability  
It is well established that two main strains of HIV-1 are
found within an infected human host: the macrophage-
tropic HIV-1 (R5 virus), which preferentially uses CCR5 as a
coreceptor during binding of the gp120 envelope protein to
CD4 on a target cell [32,33] and the T cell-tropic HIV-1 
(X4 virus), which requires CXCR4 as a coreceptor [34].
Before the identification of coreceptors, HIV-1 strains were
categorized by their ability to induce the fusion of infected
cells into a syncitia of cells [35]. Subsequently, it has been
repeatedly demonstrated that syncitia-inducing (SI) forms of
HIV-1 are most often X4 viruses, and non-syncitia inducing
(NSI) forms, most often R5 viruses. However, there are
reports of SI R5 viruses [36,37] and we therefore feel it is
not safe to define coreceptor dependency on the basis of 
this biology. 
Selectivity for either CCR5 or CXCR4 is thought to be
conferred by structural changes in the V2 and V3 loops of
the gp120 protein [38,39]. Sequence comparison
approaches using sequences from the env sequence clade of
B-subtype HIV-1 have identified susceptible positions within
the V3 loop that are often mutated to positively charged
amino acids – the so-called 11/25 rule [40]. The structural
changes potentially induced by accumulated V3 mutations
have been modelled by Sharon and colleagues, who
examined a V3 peptide derived from the MN R5 tropic
strain (V3MN) and one derived from the X4 tropic IIIB
laboratory-derived strain (V3IIIb), which has a glutamine-
arginine insertion near the tip of the V3 loop (present in
<10% of HIV-1 isolates) [41]. Remarkably, the predicted 
β-hairpin structures of these two peptides almost completely
overlie the structural features of the β-sheets of the 
CCR5 ligand CCL3L1 and the CXCR4 ligand CXCL12, 
respectively (Fig. 3). 
It has been shown in vitro that conversion between R5
and X4 strains is possible given the correct selective
pressure. For example, the genotype and coreceptor
selectivity of a cloned R5 HIV-1 virus changed to those of an
R5X4 virus after prolonged culture in lymphoid cells [39].
The selective pressure appears to involve interactions of
CXCR4 and its ligands, as specific blockade of CXCR4 using
the bicyclam AMD3100 prevented emergence of CXCR4
use. Indeed, blockade of CXCR4 in cells infected with X4
viruses led to the emergence of R5X4 dual-tropic or R5-
tropic variants [39]. The critical question of whether this
conversion between strains occurs in the human host has
not been conclusively determined, although there is growing
evidence that there are X4 quasi-species present at baseline
testing even in so-called R5-infected patients [42]. Jensen
and van ’t Wout also draw attention to the important point
that R5 and X4 comprise two distributions of viruses with a
range of mutational differences in the V3 loop [43]. Thus,
the level of mutation required for switching from a particular
R5 sequence to an X4 sequence varies. 
Human diversity: The search for tools to disarm 
HIV-1 pathogenicity? 
Despite its remarkable mutability, which provides a
successful response to immune pressure during the course of
an infection, HIV-1 is constrained by the necessity to
maintain existing, or develop new, mechanisms that
efficiently initiate an infection in a new host. Thus, if novel
affinities for alternative coreceptors develop within the viral
population of an infected host, suitable targets for these
must also be present at the sites of primary infection for
them to be retained within the population.
Given the results of the phylogenetic analysis of the
chemokine receptor family (Fig. 2), it is somewhat surprising
that CXCR4 is targeted, as it is not as closely related to
CCR5 as other receptors; this suggests that phylogenetic
analyses are not sufficiently sophisticated to examine
structural or binding site potential at present. Furthermore,
this switch in receptor tropism has been estimated to involve
between one and six amino acid substitutions [43,44],
which has reinforced the idea that R5 and X4 viruses are 
Figure 3. Analogy between the dual hairpin 
conformations formed by the HIV-1 gp120 V3 loops and
the conformations of the homologous β hairpins in MIP-1
and SDF-1. Backbone superimposition of the homologous
structures in CXCL12 (light blue), V3IIIB (grey), CCL3L1
(blue), and V3MN (dark grey). Note that the loop of V3IIIB
is extended owing to the insertion of two amino acids. 
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not derived from each other in vivo. This reasoning 
forms the basis of strategies to select patients for 
treatment with specific receptor inhibitors, as further
discussed below.
Immature mucosal dendritic cells (DCs) are likely to be
among the first cells to become infected with HIV-1. In man,
these are both CD4 and CCR5 positive [45]. Additionally,
these DCs express the C-type lectin DC-Sign, which,
although not an HIV-1 coreceptor, binds gp120 without
internalizing the virus. This bound virus is then carried by
the DCs when they migrate to secondary lymphoid organs,
which facilitates viral access to T cells [46]. 
The use of additional coreceptors by HIV-1, which has
been demonstrated using indicator cell lines in vitro has
generated much interest [47]. However, it has not been
possible to demonstrate efficient infection mediated by
these receptors expressed on peripheral blood mononuclear
cells when interactions with CCR5 are absent as a result of a
homozygous  Δ32 polymorphism, or when CXCR4 is
specifically blocked [48,49]. The CX3CR1 receptor for
CX3CL1 (fractalkine) has been identified as an HIV-1
coreceptor in vitro; a polymorphic variant of this receptor
(T280M) has been shown to occur at a higher frequency in
cohorts of rapid-progressor patients, which suggests that it
acts as an alternative coreceptor for some HIV-1 viral 
strains [50].
Analyses of polymorphic variation in large patient cohorts
provide information on the biologically limiting factors that
shape HIV-1 infectability and progression. A recent study
revealed an influence of gene dosage of the CCR5 high-
affinity ligand CCL3L1: levels higher than the population
average had protective effects on both infectability and
disease progression in different human populations [51].
This finding seems consistent with the large body of
experimental evidence showing that natural ligands for
CCR5 reduce HIV-1 infectability in a concentration-
dependent manner via competitive inhibition of gp120
binding [52]. Additionally, the binding of CCL3L1 to its
receptors has been suggested to reduce the level of host cell
cellular activity that is critical for efficient viral replication, by
reducing intracellular cyclic-AMP levels through inhibitory
G-proteins [53,54]. This is in contrast to the binding of
gp120, which appears to induce a constitutive activation of
host cell transcription factors, including AP-1 [54].   
As CCL3L1 is a proinflammatory chemokine, its
protective effect is only mediated during the course of an
inflammatory event. Under normal circumstances, there is
not a high concentration of this protein, either in the
periphery or the circulation. It is therefore tempting to
speculate that the induction of CCL3L1 and/or other
inflammatory chemokines may play a role in conferring
protection against HIV infection under selected
circumstances. Such a mechanism may be implicated in
cases of Kenyan sex workers repeatedly exposed to multiple
strains of HIV-1 who have remained uninfected [55]. These
individuals lack the protective effect of the CCR5 Δ32
mutation, but may have a chronic induction of CCL3L1
within the vaginal epithelium associated with local pro-
inflammatory signaling, triggered by the damage associated
with sexual intercourse and opportunistic sexually
transmitted infections. The enhanced levels of CCL3L1
would be expected to fall in the absence of a continuing
inflammatory stimulus, which is consistent with the loss of
protection observed in this cohort once they retired from
this profession [56].
Shift of HIV-1 from R5 to X4 variants and 
disease progression 
It is well established that R5 viruses predominate in early
HIV-1 infection and that disease progression is associated
with a shift from R5 to X4 variants [57,58]. Furthermore,
changes in coreceptor use, predominantly from CCR5 to
CXCR4, have been associated with an accelerated loss of
CD4
+ cells and a faster progression to AIDS [57,59].
Schuitemaker and colleagues reported that this switch from
R5 to X4 viruses occurred in around 50% of patients and
that the incidence of appearance of X4 variants was
increased in individuals with CD4
+ T cell counts <500/ml
[60] (summarized in Fig. 4). The presence of dual R5X4 or
mixed populations of CXCR4-using viruses may occur at all
CD4
+ cell levels and viral loads, but is more common at
lower CD4
+ cell counts and high viral loads [61].
One possible explanation for the predominance of R5
forms of the virus early in the infection is that there 
are no suitable X4 target cells during this period. This is
partly explained by the fact that CXCR4 is predominantly
expressed on the naïve, unstimulated subset of 
T lymphocytes [62]. Naïve T cells appear to be poor targets
for efficient viral replication [63]. It is possible that an
increased stimulation of these T lymphocyte subsets in late
HIV-infection might facilitate replication within these naïve 
T cells [64]. If these naïve cells are now targeted and 
killed this will impact on the CD4
+ cell frequency markedly
ultimately reducing the size of the memory CD4 pool. 
[64]. Although some studies have proposed that X4 variants
are more cytopathic than R5 HIV-1 variants [44,65], 
others have suggested that CCR5- and CXCR4-tropic 
HIV-1 are equally cytopathic for their T cell targets and 
that the accelerated loss of T cells is attributed simply to 
the different targets of the virus, as outlined above 
[66].  In vitro studies have highlighted that the binding 
of X4 viruses to CXCR4
+ T cells induces apoptosis
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independently of successful infection of the bound 
cells and that this is not a property shared by R5 viruses [67].
Manning the roadblocks: The approaching receptor
antagonist revolution? 
The discovery that individuals who are homozygous for the
CCR5 Δ32 allele are protected from HIV infection has clearly
demonstrated that viral entry is a highly effective limiting
step in the progression of HIV-1 infection [68]. Just as
significant is the fact that these individuals have no known
immunological defects related to their lack of CCR5 [68].
The corollary of these observations is the prediction that the
pharmacological ablation of CCR5 responses would not
produce harmful side effects, which has been borne out by
good tolerance to a number of different inhibitory molecules
in Phase I clinical trials [69]. 
Although it is not clear whether there is a direct switch of
viral tropism from a pure R5 HIV-1 population to dual tropic
or X4 HIV-1 variants in vivo, it is highly probable that the
viral population infecting a new host contains viruses of
mixed tropisms. This is clinically important, as the presence
of detectable X4 strains at the onset of antiretroviral therapy
is related to a worse clinical outcome [70]. 
Accumulating evidence obtained in vitro using specific
inhibitors of coreceptor binding demonstrates the lability of
coreceptor preference under focused selective pressure.
Thus, the targeting of CCR5 in patients with a mixture of R5
and X4 viruses might provide a selective pressure that favors
the X4 strain. Additionally, co-infections with other
pathogens may alter the selective environment to favor X4
strains. For example, Mycobacterium tuberculosis co-
infection has been associated with an upregulation of
CXCR4 on alveolar macrophages [71]. For this reason,
clinical trials have been careful to administer CCR5
antagonists to patients whose HIV-1 populations have been
phenotyped as R5. The CCR5 antagonists that have been
evaluated in Phase I and Phase II trials all tend to cause
dramatic reductions in viral load [69]. However, there is
evidence of an expansion of either a pre-existing R5X4 virus
or a switching of coreceptor preference via in vivo
adaptation in a small number of patients [72]. Interestingly,
the high titers of X4 virus decreased as the CCR5 antagonist
was lost from the patients’ system, perhaps reflecting
competition for CCR5
+ cellular targets. New specific
antagonists that block both CCR5 and CXCR4 are being
developed to prevent X4 expansion [73]. 
Figure 4. Co-adaptation of HIV/SIV and chemokine receptors. A: CCR5 expression predominates in cells initially exposed
to HIV-1 (macrophages, dentritic cells, mucosal T cells). B: Protective effect of high levels of certain chemokines (i.e.
CCL3L1) on HIV infectability. C: gp120-dependent, G-protein-linked activation of adenylcyclase leads to activation of
CCR5
+ cells. D: Possible immune-driven selection of HIV X4 viruses during HIV infection. E: Increased proliferation of
resting and naïve T cells (with predominantly CXCR4 receptors) in “late” HIV-infection. F: Shift to CXCR4 use of
predominant immune targets through co-infections (i.e. tuberculosis). G: Co-evolution drives selective mutations in simian
CCR5 receptors that inhibit SIV gp120 binding, with only minor effects on chemokine binding and signaling. SIV survives
without causing disease in the natural host. H: “Bottleneck-effect” - genes encoding detrimental CCR5 receptors are lost
from the host genome after encounters with highly pathogenic viruses.
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The long-term consequences of CXCR4 blockade have
not been evaluated, and initial trials of CXCR4 antagonists
were stopped following reported side effects on the Q
wave to T wave interval of the patients’ heart rhythm.
Although the next generation of CXCR4 antagonists has 
so far been well tolerated [69], the loss of signaling
through this non-redundant chemokine–chemokine
receptor system could have deleterious effects on a range
of important biological processes, including immune
responses. Thus, it may be necessary to use independent
antagonists for CCR5 and CXCR4 so that the X4 antagonist
can be withdrawn if complications arise. Although
antagonists have been reported to reduce viral loads
significantly [69], it will be important to use them as an
adjunct to current antiretroviral therapy protocols to reduce
the probability that resistant viruses emerge. This is not 
just a theoretical concern as the emergence of viral 
variants resistant to CCR5 antagonists has been described
in vitro [74]. 
Conclusion 
Comparative sequence analysis is beginning to provide
important insights into the variety of reponses that have
been selected for across the primate and lentiviral families.
These approaches are identifying susceptible and resistant
genotypes within the human population, as well as
revealing the remarkable dependency of HIV-1 on receptor
binding for entry into host cells. Recently introduced specific
antagonists to CCR5 and CXCR4 are an exciting new set of
therapeutic tools for use in the war against HIV-1
pathogenicity. Examples of successful battles of primate
species with similar viral pathogens are extremely
informative. The AGM adaptation of CCR5 to inhibit viral
envelope binding but preserve native ligand signaling should
encourage further innovations in coreceptor antagonist
design, whilst the reduction in both CCR5 and human
leukocyte antigen diversity in the chimpanzee indicates that
the adaptive immune response plays an important role in
overcoming viral pathogenicity. Ongoing studies on the
influence of genetic diversity on HIV-1 and -2 and SIV 
in man and primates will continue to identify critical
processes involved in initial infection and early adaptive 
immune responses. 
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